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Methods: In protocol 9801, 401 pts with BM from any primary tumor 
were randomized to receive WBRT alone (30 Gy/10 fractions) or MGd, 
5 mg/kg qd x 10 days, with WBRT. The subgroup of 251 pts with 
NSCLC is included in this analysis. In protocol 0211, 554 pts with BM 
from NSCLC were randomized to the same treatments. In both studies, 
eligibility included a KPS ≥ 70, no liver metastases, and ≤ 1 site of 
extracranial metastasis. In both studies, patients underwent a battery of 
neurocognitive tests measuring memory and executive function at base-
line and all subsequent monthly follow-up visits. Progressions were 
deﬁned as a conﬁrmed decline from baseline of 1.5 standard deviations, 
corrected for age and educational background.
Results: 805 pts received WBRT (N=403) or MGd+WBRT (N=402). 
Most pts had multiple BM (81%), extracranial metastases (47%) 
and presented with neurologic deﬁcits (84%). Treatment arms were 
balanced for key prognostic factors. At baseline, 77% of all patients 
had some degree of neurocognitive deﬁcit with 18% having one test 
result abnormal, 20% having two, 18% having three, 16% having four 
and 5% having all ﬁve test results abnormal. Memory was the most 
frequently impaired function (57%). Baseline neurocognitive impair-
ments were balanced across treatment arms. Patients treated with 
MGd+WBRT were less likely during follow-up to show evidence of 
neurocognitive progression in memory function (HR=0.80, p=0.047), 
in executive function (HR=0.74, p=0.028) or in a combined score for 
all tests, (HR=0.78, p=0.02).
Conclusions: Consistent with the delay in time to clinical neuro-
logic progression seen in a previous pooled analysis, treatment with 
MGd+WBRT decreased progression in each function measured by 
standardized neurocognitive testing in the pooled dataset from 2 ran-
domized phase III trials.
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Background: In early stage NSCLC, neoadjuvant chemotherapy is a 
promising option, although conclusive evidence is yet to be supplied. 
The NATCH trial was designed in order to address whether neoadjuvant 
or adjuvant paclitaxel(P)/carboplatin(C)improves disease-free survival 
compared to surgery alone in early-stage NSCLC. Analyses of toxicity, 
response rate, resectability rate and surgical mortality rates have now 
been carried out on patients randomized to the neoadjuvant arm.
Methods: Clinical stage I (> 2 cm), II, T3N1 NSCLC consenting 
patients are randomized to surgery alone or 3 cycles of neoadjuvant PC 
(P:200 mg/m2/ C AUC:6 on day 1 every 3wk), or surgery followed by 3 
cycles of adjuvant PC at the same schedule. This prospective, random-
ized trial planned to include 624 patients.
Results: Between April 2000 and March 2007, 623 patients have been 
accrued, 201 on the neoadjuvant arm; 211 on the adjuvant arm and 
211 on the surgery arm. On the neoadjuvant arm, demographic data is 
now available for 162 patients: 89% male; median age 64 years (range, 
37-78); 45% PS 0; 53% squamous cell, 27% adenocarcinoma, 13% 
large cell; 7% stage IA, 64% IB, 2% IIA, 24% IIB, 2.5% T3N1. To 
date, neoadjuvant chemotherapy has been well tolerated. No unex-
pected toxicities have been seen with 12% of patients having grade 3-4 
neutropenia and 43% grade 1-2 anemia. Major radiographic response 
has been observed in 59% of patients and progression during chemo-
therapy occurred in 6%. No patient characteristics were predictive for 
clinical response. At thoracotomy resection procedures were: lobec-
tomy or bilobectomy in 70%; pneumonectomy in 26%; and explorative 
thoracotomy due to unresectable disease in 3% of patients. Thirty-day 
post-operative mortality was 4%. At surgery, 9% patients had patho-
logic complete response; 75% N0-1 disease (with persistent T tumor), 
and 15% had pathologic N2 disease. 
Conclusion: Our ﬁndings suggest that neoadjuvant chemotherapy 
in early NSCLC is feasible with manageable toxicity and with good 
resectability rates. Mature survival results of the NATCH trial are 
expected in 2009.
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Background: Surgery offers the best chance of cure for patients with 
NSCLC, but the 5-year survival rate is modest, and improvements are 
urgently required. Following striking results in favour of neo-adjuvant 
chemotherapy in 2 small trials, the current trial was designed to investi-
gate whether, in patients with operable NSCLC of any stage, platinum-
based chemotherapy given prior to surgery would improve outcomes.
Methods: The primary endpoint was overall survival, and secondary 
endpoints were: quality of life, pathological staging, resectability rates, 
extent of surgery, and time to and site of relapse. The trial was designed 
to detect a 15% improvement in 3-year survival (from 40% to 55%) with 
neo-adjuvant chemotherapy (5% signiﬁcance level, 90% power), which 
required 450 patients and 233 events (deaths). Patients were randomised 
to receive either surgery alone (S), or 3 cycles of platinum-based che-
motherapy prior to surgery (CT-S), clinicians choosing (pre-randomisa-
tion) the chemotherapy from 6 standard regimens. Quality of Life was 
assessed by patients completing the SF-36 questionnaire at baseline 
(pre-randomisation), 6 and 12 months, and then annually to 5 years. 
Copyright © 2007 by the International Association for the Study of Lung Cancer S337
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Results: 519 patients were randomised (S: 261, CT-S 258) from 70 
centres in the UK, the Netherlands, Germany and Belgium. The median 
age of the patients was 63 years, 72% were male, 55% were perfor-
mance status (PS) 0, 44% PS 1, 49% had squamous cell histology, 
61% had stage I, 31% stage II, and 7% stage III disease. 12% patients 
received mitomycin/vinblastine/cisplatin, 7% mitomycin/ifosfamide/
cisplatin, 45% vinorelbine/cisplatin, 12% carboplatin/docetaxel, 
and 25% cisplatin/gemcitabine. The trial showed that neo-adjuvant 
chemotherapy was feasible (76% of patients received all 3 cycles of 
chemotherapy), resulted in a good response rate (4% CR, 45% PR), and 
appeared to cause down-staging in approximately 13% of patients. The 
use of pre-operative chemotherapy did not affect the type of surgery 
performed (lobectomy: S 61%, CT-S 66%, pneumonectomy: S 32%, 
CT-S 28%), or the post-operative complication rate. Apart from a re-
duction in ‘role physical’ (problems with work or other daily activities 
as a result of physical health) in the CT-S group at 6 months, no signiﬁ-
cant differences were observed in quality of life between the treatment 
groups. The time to (and sites of) relapse did not differ between the 
regimens, except that more patients in the CT-S group developed brain 
metastases (S 16, CT-S 31). A total of 244 patients have died (S 122, 
CT-S 122), and there is no evidence of a difference in terms of overall 
survival (HR 1.02, 95% CI 0.80, 1.31). Median, 1, 2 and 5 year sur-
vival in the S group were: 54 months, 83%, 69% and 45% respectively, 
and applying the HR to these ﬁgures gives, for the CT-S group: 53 
months, 83%, 69% and 44% respectively. Exploratory analyses showed 
no evidence that any subgroup beneﬁted signiﬁcantly more or less from 
neo-adjuvant chemotherapy.
Conclusions: This intergroup trial, which is the largest trial of neo-ad-
juvant chemotherapy in patients with resectable NSCLC, indicated that 
the addition of neo-adjuvant platinum-based chemotherapy did not lead 
to a beneﬁt in overall survival.
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Background: Building on a previous IPD meta-analysis of CT (BMJ 
1995;311:899-909) which suggested that CT may have a role in the 
treatment of NSCLC, we have carried out a new, up-to-date IPD meta-
analysis. This includes RCTs, regimens and outcomes that were not 
available in 1995. This new meta-analysis examines the role of CT in 7 
treatment comparisons. Here we report the effectiveness of supportive 
care plus CT compared with supportive care alone.
Methods: We conducted a systematic search for RCTs followed by the 
central collection, checking and re-analysis of updated IPD. Results 
from individual RCTs were combined using the stratiﬁed (by trial) log 
rank test to calculate individual and pooled hazard ratios (HRs).
Results: IPD were obtained from 15 RCTs and 2666 patients. This 
adds 6 RCTs and 1702 patients to the 1995 analyses. 11 RCTs used 
cisplatin-based CT regimens, 4 RCTs used single agent CT (etoposide, 
navelbine, gemcitabine, paclitaxel). The results show a highly sig-
niﬁcant beneﬁt of CT on survival (HR=0.78 95% Conﬁdence Interval 
0.71-0.84, p<0.000001), with an absolute beneﬁt of 8% (from 20% 
to 28%) at 12 months across all patients. There was no evidence of a 
difference in effect (p=0.69) between trials that used cisplatin-based 
regimens (11 RCTs, HR=0.76), etoposide alone (1 RCT, HR=0.87) or 
newer single agents (3 RCTs, HR=0.79) (Interaction p=0.69). There 
was no evidence that any patient subgroup deﬁned by age, sex, stage or 
histology beneﬁted more or less from CT. However, owing to differing 
underlying survival rates, the absolute beneﬁt of CT at 12 months did 
vary according to WHO/ECOG (or equivalent) performance status. PS 
0=8% (from 26% to 34%), PS 1=8% (from 18% to 26%), PS 2=5% 
(from 6% to 11%) and PS 3=4% (from 5% to 9%).
Conclusion: The results demonstrate a substantial and consistent rela-
tive beneﬁt of CT in advanced NSCLC. The effectiveness of newer 
agents such as navelbine, paclitaxel and gemcitabine (used as single 
agents) appears to be similar to that of cisplatin combined with older 
agents such as vindesine and mitomycin C. The absolute effect of CT 
varied according to performance status.
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Background: Divergent opinions exist whether patients who present 
with advanced NSCLC and performance status (PS) 2 beneﬁt from ei-
ther standard doublet chemotherapy or, due to treatment-related toxicity 
and limited survival potential, single agent therapy is more appropriate 
in these pts. 
Methods: Linear regression analysis of the data from the two largest 
phase 3 trials of de novo therapy in PS 2 pts, STELLAR 3 and 4, was 
performed to identify patient subsets that would beneﬁt from either 
doublet or singlet therapy. STELLAR 3 randomized 400 pts to either 
paclitaxel + carboplatin or paclitaxel poliglumex (PPX) + carboplatin. 
STELLAR 4 randomized 396 patients to single agent PPX or to investi-
gator choice of single agent vinorelbine or gemcitabine. Both trials had 
identical inclusion and exclusion criteria. Both arms of each trial had 
similar outcomes (HR = 0.95 and 0.97; PPX to control for STELLAR 3 
and 4, respectively). 
Results: In the univariate model, signiﬁcant predictors of compromised 
survival (p ≤ 0.01) were: albumin <3.5 gm, extrathoracic metastases 
excluding brain (ETM), hemoglobin <11 gm, weight loss >5%, LDH 
>200 IU, geographic region (US v. rest of world), any tobacco his-
tory, > 2 comorbid conditions, and disease stage (4 versus <4). In the 
multivariate model, only albumin, ETM, >2 comorbidities, and tobacco 
history were signiﬁcant (p <0.0001). Patients with none of these four 
risk factors had median survival of 473 days; survival decreased in a 
stepwise manner to 96 days in pts with all four risk factors. To analyze 
the effect of singlet v. doublet therapy on outcome, pts with three or 
